Mettler Toledo
MTD
$1290.84
-1.90%
Mettler-Toledo International is a global leader in supplying precision weighing and analytical instruments, serving customers primarily in the life sciences (55% of sales), industrial (40%), and food retail (5%) industries. The company is a dominant market leader in weighing instrumentation, controlling over half of the global market for laboratory balances, and its competitive identity is built on high-quality, mission-critical equipment for scientific research and quality control. The current investor narrative revolves around navigating a post-pandemic normalization in demand, particularly in its core life sciences segment, while demonstrating resilient profitability and margin expansion despite a challenging macroeconomic environment, as evidenced by recent quarterly results showing solid year-over-year revenue growth.…
MTD
Mettler Toledo
$1290.84
MTD 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Mettler Toledo's 12-month outlook, with a consensus price target around $1678.09 and implied upside of +30.0% versus the current price.
Average Target
$1678.09
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$1033 - $1678
Analyst target range
Analyst coverage for MTD appears limited in the provided dataset, with only 5 analysts contributing to estimates for revenue and EPS, implying insufficient broad consensus data for a traditional target price and recommendation breakdown. The lack of a clear consensus target price and Buy/Hold/Sell distribution suggests this may be a case of limited coverage, which is somewhat unusual for a company of its market cap ($28.7B) and could lead to higher volatility and less efficient price discovery. The available institutional ratings show a mix of opinions, with recent actions including an upgrade to Buy from Jefferies and maintained Overweight/Outperform ratings from Barclays and Evercore ISI, indicating a generally positive but not unanimous bias among the firms that do provide coverage.
Bulls vs Bears: MTD Investment Factors
The bull case for MTD is anchored in its unassailable market leadership, exceptional profitability, and resilient cash generation, which justify a premium valuation. The bear case focuses on its elevated valuation relative to recent history, high volatility, and concentration in a post-pandemic normalizing segment. Currently, the bearish evidence holds a slight edge due to the stock's premium valuation and recent sharp technical correction within a broader downtrend. The single most important tension in the investment debate is whether MTD's premium P/E multiple (33.06x trailing) can be sustained by a reacceleration of growth in its core life sciences segment, or if it will compress further as the post-pandemic demand cycle fully normalizes.
Bullish
- Dominant Market Leadership: MTD controls over 50% of the global market for laboratory balances, providing a durable competitive moat in mission-critical scientific equipment. This leadership underpins its ability to maintain premium pricing and high gross margins of 57.52%.
- Exceptional Profitability & Cash Flow: The company generates robust operating margins of 30.39% and a net margin of 21.59%. It produces substantial free cash flow, with TTM FCF of $848.6M, which funds aggressive share buybacks and supports its financial structure despite negative shareholder equity.
- Resilient Post-Pandemic Growth: Despite normalization from peak pandemic demand, MTD delivered solid 8.1% YoY revenue growth in Q4 2025. This demonstrates underlying demand resilience across its core life sciences (55% of sales) and industrial (40%) segments.
- Positive Analyst Sentiment: Recent institutional actions include an upgrade to Buy from Jefferies and maintained Overweight/Outperform ratings from Barclays and Evercore ISI. This indicates a positive bias among covering analysts, supporting the investment narrative.
Bearish
- Premium Valuation vs. Own History: The trailing P/E of 33.06x is above its recent quarterly historical range (e.g., 24.86x at Q4 2025, 29.04x at Q3 2025). This suggests the stock is trading at a premium to its own recent past, leaving it vulnerable to multiple compression.
- High Volatility & Sharp Correction: With a beta of 1.435, MTD is 44% more volatile than the market. It recently experienced a maximum drawdown of -25.05% and is down -10.78% over the last 3 months, indicating significant price risk and investor uncertainty.
- Limited Analyst Coverage: Only 5 analysts contribute to estimates, and there is no clear consensus target price. This limited coverage can lead to less efficient price discovery and higher volatility, as seen in the recent sharp price swings.
- Revenue Concentration Risk: 55% of sales are concentrated in the life sciences segment, which is navigating post-pandemic demand normalization. A slowdown in biopharma or academic research spending could disproportionately impact overall growth.
MTD Technical Analysis
The stock is in a sustained downtrend from its recent highs, with a 1-year price change of +32.81% but a more recent 3-month decline of -10.78%. As of the latest close at $1,325.01, the price is trading at approximately 76% of its 52-week range ($962.54 to $1,525.17), indicating it has retreated significantly from its highs but remains well above its lows, suggesting a phase of consolidation after a sharp correction. Recent momentum shows a stark divergence: while the 1-year trend is positive, the 3-month trend is negative at -10.78%, and the 1-month trend has turned positive at +7.82%, signaling a potential short-term recovery attempt or oversold bounce within the broader corrective phase. Key technical support is anchored at the 52-week low of $962.54, while resistance sits at the 52-week high of $1,525.17; a sustained move above the recent recovery high near $1,335 would be needed to signal a more convincing reversal. The stock exhibits high volatility with a beta of 1.435, meaning it is approximately 44% more volatile than the broader market, which is a critical consideration for risk management given its recent maximum drawdown of -25.05%.
Beta
1.44
1.44x market volatility
Max Drawdown
-22.4%
Largest decline past year
52-Week Range
$963-$1525
Price range past year
Annual Return
+27.0%
Cumulative gain past year
| Period | MTD Return | S&P 500 |
|---|---|---|
| 1m | +7.0% | +4.6% |
| 3m | -11.6% | +1.4% |
| 6m | -4.3% | +5.6% |
| 1y | +27.0% | +33.5% |
| ytd | -8.5% | +2.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MTD Fundamental Analysis
Revenue growth remains positive but has moderated from peak pandemic levels; Q4 2025 revenue was $1.13 billion, representing a solid 8.1% year-over-year increase, and segment data shows the Laboratory segment ($638.2M) continues to be the largest driver, followed by Industrial ($437.1M). Profitability is robust with the company generating a net income of $285.8 million in Q4 2025, supported by strong gross margins of 58.05% and an operating margin of 30.39%, indicating effective cost control and pricing power even as growth normalizes. The balance sheet and cash flow position is healthy, with the company generating substantial free cash flow (TTM FCF of $848.6M), a current ratio of 1.14 providing adequate short-term liquidity, and a negative debt-to-equity ratio of -99.14 (a function of negative shareholder equity due to aggressive share buybacks) which, while atypical, is supported by strong and consistent operating cash generation.
Quarterly Revenue
$1.1B
2025-12
Revenue YoY Growth
+0.08%
YoY Comparison
Gross Margin
+0.58%
Latest Quarter
Free Cash Flow
$848648000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MTD Overvalued?
Given the company's consistent profitability with a net margin of 21.59%, the primary valuation metric is the P/E ratio. The trailing P/E stands at 33.06x, while the forward P/E is lower at 25.88x, indicating the market expects earnings growth to continue, with the gap suggesting an anticipated EPS growth rate embedded in the forward multiple. Compared to sector averages, the stock's trailing P/E of 33.06x and PS ratio of 7.14x are not directly comparable without a provided industry average, but the elevated multiples generally command a premium justified by the company's market leadership, high margins (gross margin of 57.52%), and strong return on assets of 20.35%. Historically, the current trailing P/E of 33.06x is above the recent quarterly historical range observed in the data (e.g., 24.86x at Q4 2025, 29.04x at Q3 2025), suggesting the stock is trading at a premium to its own recent history, which may reflect optimism about future earnings recovery or a compression from previously even higher levels.
PE
33.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 25x~45x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: MTD's primary financial risk stems from its valuation, not its operations. The trailing P/E of 33.06x is high and leaves the stock exposed to significant multiple compression if growth decelerates below market expectations. Operationally, while margins are robust, 55% revenue concentration in life sciences creates vulnerability to a cyclical downturn in biopharma capital expenditure or academic funding. The company's negative shareholder equity (-99.14 D/E) is a structural risk, though it is currently mitigated by strong TTM free cash flow of $848.6M and a healthy current ratio of 1.14.
Market & Competitive Risks: The stock's high beta of 1.435 indicates it is highly sensitive to broader market swings, particularly detrimental in a risk-off environment for growth stocks. Trading at a PS ratio of 7.14x and a forward P/E of 25.88x, it carries valuation compression risk if sector multiples contract or if its growth premium erodes. Competitive risks are muted given its dominant 50%+ market share in lab balances, but the risk lies in technological disruption or pricing pressure in adjacent analytical instrument markets. The limited analyst coverage (only 5 analysts) exacerbates market risk by potentially amplifying price moves on limited news.
Worst-Case Scenario: The worst-case scenario involves a combination of a deeper-than-expected slowdown in life sciences demand, triggering a mid-single-digit revenue decline, concurrent with a broader market sell-off that compresses growth stock multiples. This could lead to a rapid derating, with the P/E falling towards 20x. In this adverse scenario, the stock could realistically retest its 52-week low of $962.54, representing a potential downside of approximately -27% from the current price of $1,325.01. The recent maximum drawdown of -25.05% provides a recent precedent for this magnitude of loss.